KK2 - From the June 22 PR - BoM2 

All or most BETonMACE2 patients to receive top standard of care, including maximized use of SGLT2 inhibitors (SGLT2i)

BETonMACE2 to increase enrichment of chronic kidney disease (CKD) patients, potentially including those with lower baseline renal function

Based on BETonMACE results, the FDA encouraged the evaluation of a non-alcoholic fatty liver disease (NAFLD) subgroup as well as related exploratory endpoints

Just some small changes that could have a profound effect on the final outcome as it was these groups that had the best results in BETonMACE.

Best to have the scientists chime in as I am not in that catagory.

tada